Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck COVID-19 pill success slams Moderna shares, shakes up healthcare sector

10/01/2021 | 04:13pm EST
FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, New Jersey

(Reuters) - Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the healthcare sector on Friday, sending the drugmaker's stock price soaring while denting high-flying shares of vaccine companies and makers of other coronavirus therapies.

Merck shares jumped as much as 12.3% and hit their highest level since February 2020 after data showed the company's pill molnupiravir https://www.reuters.com/business/healthcare-pharmaceuticals/mercks-covid-19-pill-cuts-risk-death-hospitalization-by-50-study-2021-10-01 could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19. Experts hailed the news as potentially a huge advance in the fight against COVID-19.

At the same time, shares of vaccine makers such as Moderna Inc, Pfizer Inc and partner BioNTech SE were hit, with some analysts saying the promise of an oral drug that can be taken at home could change the public perception of risks associated with COVID-19.

"We see modest perceived headwind to vaccine stocks such as MRNA (Moderna) if the market thinks people will be less afraid of COVID-19 and less inclined to get vaccines, if there is a simple pill that can treat COVID-19," Jefferies analyst Michael Yee said in a client note.

Moderna shares tumbled 13% in midday trading, while Pfizer, which is developing a COVID-19 pill of its own, fell 1.3%. U.S. shares of BioNTech dropped 11%.

For Moderna investors, the Merck news presented an opportunity to lock in gains after an already stunning run. Shares of Moderna, which were added to the S&P 500 in mid July, remain up some 220% in 2021 despite Friday's declines. BioNTech's shares were also still up about 200% for the year, even with Friday's fall. The Merck news is a "great reason for folks to be taking profits off the table" in Moderna and BioNTech shares, said Sahak Manuelian, head of equity trading at Wedbush Securities. "These moves can get exacerbated to the downside given the momentum they have had to the upside."

Shares of other companies with COVID-19 vaccines also fell, with AstraZeneca down 2% and Novavax falling 16%.

Companies with other COVID-19 therapies that are administered intravenously or through injection also traded lower, with Regeneron Pharmaceuticals In down nearly 5% and Gilead Sciences Inc off about 2%.

Healthcare was the only one of the 11 S&P 500 sectors in negative territory in mid-day trading, falling 0.5%. "We see molnupiravir, with its oral format as a clear game changer that is likely to meaningfully impact not just the treatment paradigm for COVID-19 but also has potential utility in the prevention setting," Piper Sandler analyst Christopher Raymond said in a research note.

Merck is conducting a late-stage trial to see if its antiviral pill can prevent COVID-19 infection, in addition to the study that showed it can significantly cut hospitalization and death in those already infected.

Merck, whose shares were last up about 9%, leads the race in developing the first oral antiviral medication for COVID-19. Rivals such as Pfizer and Swiss drugmaker Roche Holding AG with partner Atea Pharmaceuticals Inc are running late-stage trials of their pills. Atea shares were up 19%.

Merck, which discontinued its own COVID-19 vaccine program, had seen its shares fall about 4% for the year through Thursday, before they moved into positive territory for 2021 on Friday.

"Merck has kind of been dead in the water to investors for the past couple of quarters," said Kevin Gade, portfolio manager with Bahl & Gaynor, which owns Merck shares. "This shows their R&D engine is not dead and they were first ... in what could be a multi-billion dollar opportunity."

(Reporting by Lewis Krauskopf in New York and Manojna Maddipatla in Bengaluru; Editing by Ira Iosebashvili and Bill Berkrot)

By Lewis Krauskopf and Manojna Maddipatla

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.72% 8338 Delayed Quote.13.00%
ATEA PHARMACEUTICALS, INC. 3.19% 8.09 Delayed Quote.-80.64%
GILEAD SCIENCES, INC. -2.43% 68.93 Delayed Quote.18.31%
MODERNA, INC. -4.36% 352.43 Delayed Quote.237.35%
NOVAVAX, INC. 7.56% 208.63 Delayed Quote.87.10%
REGENERON PHARMACEUTICALS -2.73% 636.53 Delayed Quote.31.76%
ROCHE HOLDING AG 0.82% 362.6 Delayed Quote.16.39%
11/26ATEA PHARMACEUTICALS, INC. : Regulation FD Disclosure (form 8-K)
11/22Atea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
11/18SVB Leerink Downgrades Atea Pharmaceuticals to Market Perform From Outperform, Sets $11..
11/17Health Care Stocks Manage Modest Gains Wednesday
11/17Top Midday Decliners
11/17Health Care Stocks Moderately Higher This Afternoon
11/17GLOBAL MARKETS LIVE : Tesla, Experian, Roche, Activision, Amazon...
11/17Atea Pharma Shares Drop 16% After Collaboration With Roche Terminated
11/17Wall Street Set to Open Largely Flat, Stabilizing After Boost From Data, Retail Earning..
11/17Top Premarket Decliners
More news
Analyst Recommendations on ATEA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 252 M - -
Net income 2021 23,8 M - -
Net cash 2021 666 M - -
P/E ratio 2021 33,3x
Yield 2021 -
Capitalization 672 M 672 M -
EV / Sales 2021 0,03x
EV / Sales 2022 -1,35x
Nbr of Employees 56
Free-Float 81,6%
Duration : Period :
Atea Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ATEA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 8,09 $
Average target price 16,25 $
Spread / Average Target 101%
EPS Revisions
Managers and Directors
Jean-Pierre Sommadossi Chairman, President & Chief Executive Officer
Andrea J. Corcoran Chief Financial Officer, Secretary & EVP-Legal
Maria Arantxa Horga Chief Medical Officer
Keith Pietropaolo Senior Vice President-Clinical Operations
Claudio Avila Senior Vice President-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE331.48%84 953
WUXI APPTEC CO., LTD.28.27%66 734